Latin American Countries to Be 1st to Receive Avifavir COVID-19 Drug - RDIF
VLADIVOSTOK, July 11 (Sputnik) - Brazil and other Latin American countries with an high incidence of COVID-19 will be the first to receive the Avifavir antiviral drug, the Russian Direct Investment Fund's (RDIF) CEO, Kirill Dmitriev, said on Saturday.
"The video conference with almost 1,500 representatives from across Latin America today confirmed the high levels of foreign interest in Avifavir. We wish to thank all the conference’s participants and are ready to work in partnership to export the drug and support Latin American states in their fight against the pandemic," Dmitriev said, as quoted in a press release, following the online presentation of Avifavir to the representatives of Latin American and Caribbean states.
The executive also said during a televised interview that his organization had already received requests for the supply of Avifavir from more than 50 countries.
"Our priority is those countries where the number of coronavirus infections is sharply increasing. This is, of course, Brazil and many other Latin American countries," Dmitriev said.
Avifavir, the first Russian drug against COVID-19, was approved by the country's Health Ministry in late May. It has proven 90 percent effective in treating the coronavirus disease during trials. On Wednesday, the RDIF asked the ministry to allow outpatient administration of Avifavir to coronavirus patients who undergo treatment at home.
Earlier this week, the Russian Ministry of Industry and Trade received requests for the supply of Avifavir from the Commonwealth of Independent States member countries, Latin American, European and Southeast Asian countries.